نتایج جستجو برای: anti tnf

تعداد نتایج: 402081  

Tumor necrosis factor alpha (TNF-α) expression amplifies to excess amounts in several disorders such as rheumatoid arthritis and psoriasis. Although, Anti-TNF biologics have revolutionized the treatment of these autoimmune diseases, formation of anti-drug antibodies (ADA) has dramatically affected their use. The next generation antibodies (e.g. Fab, scFv) have not only reduced resulted immunoge...

Journal: :Inflammatory bowel diseases 2017
Stephan R Vavricka Martin Gubler Claudine Gantenbein Muriel Spoerri Florian Froehlich Frank Seibold Marijana Protic Pierre Michetti Alex Straumann Nicolas Fournier Pascal Juillerat Luc Biedermann Jonas Zeitz Benjamin Misselwitz Michael Scharl Henriette Heinrich Christine N Manser Ekaterina Safroneeva Raja Affendi Raja Ali Gerhard Rogler Alain M Schoepfer Thomas Greuter

BACKGROUND Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS)...

2010
Girindra Raval Paulette Mehta

Biologic therapy has increasingly been used in the treatment of chronic diseases. Tumor necrosis factor (TNF) is a cytokine implicated in the pathogenesis of rheumatoid arthritis and inflammatory bowel disease. Anti-TNF therapy is being used in the treatment of these conditions. Since the introduction of anti-TNF agents, there have been many case reports of development of malignancy after the i...

Journal: :Annals of the rheumatic diseases 2017
Joachim Sieper Atul Deodhar Helena Marzo-Ortega Jacob A Aelion Ricardo Blanco Tseng Jui-Cheng Mats Andersson Brian Porter Hanno B Richards

BACKGROUND There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375). METHODS Subjects with active AS (N=219) received secukinumab (150 or 75...

2017
Petros P. Sfikakis Aikaterini Arida Stylianos Panopoulos Kalliopi Fragiadaki George Pentazos Katerina Laskari Maria Tektonidou Nikos Markomichelakis

Objective. To test the hypothesis that remission of Behc et’s disease (BD) in patients with severe vital organ involvement is maintained after withdrawal of successful anti–tumor necrosis factor (anti-TNF) treatment. Methods. This single-center, retrospective, longitudinal outcomes study focused on consecutive patients with disease refractory to treatment with conventional immunosuppressant age...

Journal: :The Journal of infectious diseases 2003
Anita W Rijneveld Sandrine Florquin Thomas Hartung Peter Speelman Tom van der Poll

Treatments aimed at inhibition of tumor necrosis factor (TNF) in patients with sepsis have been unsuccessful. Up to 50% of such patients suffer from pneumonia. To determine the effect that treatment with anti-TNF has on pneumococcal pneumonia, mice were intranasally inoculated with Streptococcus pneumoniae and, 25 h later, treated with 1 of the following: (1) control antibody, (2) anti-TNF, (3)...

2014
Khaldoon M Alawneh Mahmoud H Ayesh Basheer Y Khassawneh Salwa Shihadeh Saadeh Mahmoud Smadi Khaldoun Bashaireh

BACKGROUND A high rate of infection has been reported in patients receiving treatment with anti-tumor necrosis factor (anti-TNF). This study describes the rate of and risk factors for serious infections in patients receiving anti-TNF agents in Jordan. METHODS This retrospective observational study was conducted at a large tertiary referral center in the north of Jordan. Between January 2006 a...

Journal: :Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2014
Xi Xie Fen Li Jin-Wei Chen Jia Wang

Anti-tumor necrosis factor-α (TNF-α) biological agents, including soluble TNF-α receptors and anti-TNF-α monoclonal antibodies, bring new hope for treating rheumatic diseases such as rheumatoid arthritis, but also increase the risk of infection, especially tuberculosis (TB) infection. Recent findings have shown that the physiological TNF-mediated signaling was somehow impaired by TNF antagonist...

Journal: :Journal of Crohn's and Colitis 2023

Abstract Background Immunogenicity to anti-TNF agents is associated with loss of response in inflammatory bowel disease (IBD). However, the efficacy different strategies restore favourable pharmacokinetics and/or clinical upon detection anti-drug antibodies (ADA) has not been widely studied. We evaluated success leading remission ADA disappearance (in patients continuing same anti-TNF), IBD. Me...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید